Puchelle E, Aug F, Polu J M
Eur J Clin Pharmacol. 1978 Nov 27;14(3):177-84. doi: 10.1007/BF02089957.
Twenty patients with stable chronic bronchitis entered a double-blind study in which changes in clinical and respiratory function and biochemical and rheological variations were examined after treatment with the mucoregulator S-carboxy-methyl-cysteine (S.C.M.C.). After one week of single-blind placebo, a two week double-blind study was initiated with placebo or oral S.C.M.C. 3 g/24h. After two weeks, a significant clinical improvement was observed in patients treated with S.C.M.C. During treatment, there was no change in respiratory function, although a drop in FEV1/VC was noted in the placebo group. A significant increase in the viscosity of the expectorations was observed after treatment with S.C.M.C. for two weeks. The levels of secretory IgA and of serum albumin in the expectorations remained stable, whereas in the placebo group, there was a slight but significant increase in serum albumin. In this group of non-infected chronic bronchitic patients, S.C.M.C. appeared to normalize the secretory function of the bronchial mucosa by preventing inflammation and enhancing the viscoelastic properties of bronchial secretions.
20例稳定期慢性支气管炎患者进入一项双盲研究，该研究观察了黏液调节剂S-羧甲基半胱氨酸（S.C.M.C.）治疗后临床及呼吸功能的变化以及生化和流变学改变。在单盲安慰剂治疗一周后，开始为期两周的双盲研究，给予安慰剂或口服S.C.M.C. 3 g/24小时。两周后，接受S.C.M.C.治疗的患者临床症状有显著改善。治疗期间，呼吸功能无变化，尽管安慰剂组的第一秒用力呼气容积/肺活量（FEV1/VC）有所下降。S.C.M.C.治疗两周后，痰液黏度显著增加。痰液中分泌型IgA和血清白蛋白水平保持稳定，而安慰剂组血清白蛋白略有但显著增加。在这组未感染的慢性支气管炎患者中，S.C.M.C.似乎通过预防炎症和增强支气管分泌物的黏弹性特性使支气管黏膜的分泌功能恢复正常。
